| abstract |
Heterocyclic compounds of formulas I, II and III are described herein together with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts and metabolites. The compounds described herein, and polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, are PAD4 inhibitors, and many disorders such as rheumatoid arthritis, vasculitis , Systemic lupus erythematosus, skin lupus erythematosus, ulcerative enteritis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis may be useful. Compounds of formulas I, II and III, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, and compounds of formulas I, II, III, or Methods of preparing pharmaceutical compositions comprising pharmaceutically acceptable salts thereof are also described. [Formula I] [Formula II] [Formula III] |